Scarica l'app Stockscreener
0.8253
9.31%
-0.0847
Dopo l'orario di chiusura:
.82
-0.0053
-0.64%
Precedente Chiudi:
$0.91
Aprire:
$0.8945
Volume 24 ore:
5.50M
Relative Volume:
0.98
Capitalizzazione di mercato:
$12.23M
Reddito:
$200.00K
Utile/perdita netta:
$-10.95M
Rapporto P/E:
-0.4181
EPS:
-1.9738
Flusso di cassa netto:
$-10.78M
1 W Prestazione:
+111.56%
1M Prestazione:
+139.22%
6M Prestazione:
-45.70%
1 anno Prestazione:
-56.33%
Intervallo 1D:
$0.7801
$0.8945
Intervallo di 1 settimana:
$0.39
$1.13
Portata 52W:
$0.28
$6.2299
Soligenix Inc Stock (SNGX) Company Profile
Nome
Soligenix Inc
Settore
Industria
Telefono
609-538-8200
Indirizzo
29 EMMONS DRIVE, PRINCETON
Compare SNGX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
0.8253 | 13.49M | 200.00K | -10.95M | -10.78M | -1.9738 |
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.59B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
600.66 | 64.45B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
836.09 | 51.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.63 | 40.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
163.68 | 33.48B | 742.00K | -1.37B | -1.07B | -7.0731 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-07-28 | Downgrade | Dawson James | Buy → Neutral |
| 2018-01-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2017-08-14 | Reiterato | Maxim Group | Buy |
| 2017-07-17 | Iniziato | H.C. Wainwright | Buy |
Soligenix Inc Borsa (SNGX) Ultime notizie
Soligenix, Inc. Files SEC Form 8-K for May 28, 2026 – Company Information and Legal Exhibits - Minichart
Soligenix Expands At-The-Market Equity Financing Capacity - TipRanks
Soligenixincreases maximum offering under sales agreement by $2.96 million - marketscreener.com
Soligenix raises at‑market share capacity by $2.956M under sales agreement - TradingView
Soligenix (NASDAQ: SNGX) raises at-the-market stock capacity by $2.96M - Stock Titan
Soligenix (NASDAQ: SNGX) raises ATM ceiling to $2.96M under Sales Agreement - Stock Titan
Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX - RTTNews
Soligenix Company Profile & Introduction - Moomoo
Soligenix more than doubles as traders react to Ebola-outbreak vaccine-platform update - Quiver Quantitative
Soligenix (SNGX) stock soars 72% on ThermoVax platform promise amid Ebola outbreak caused by Bundibugyo virus - MSN
$AIM ImmunoTech (AIM.US)$ easiest money i ever made $Soligenix (SNGX.US)$ you 2 booboo - Moomoo
Soligenix (SNGX) Stock Soars 110% as Ebola Outbreak Puts Vaccine Hopes on the Table - MEXC
SNGX Stock Pops On Heavy Volume As Traders Hunt Volatility - StocksToTrade
Soligenix Stock Nearly Doubles Before the Bell as Ebola Vaccine Hopes Put Tiny Biotech Back in Play - TechStock²
$Soligenix (SNGX.US)$ - Moomoo
Top Premarket Gainers - Moomoo
SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail Frenzy - Yahoo Finance
Trending Stocks Today | Soligenix Soars 133.91% Pre-Market - Moomoo
$Soligenix (SNGX.US)$ checkmate [Share Link: Join us in the TradersLink chat.] - Moomoo
Dow Jumps Over 300 Points; Dick's Sporting Shares Fall After Q1 Results - Sahm
Soligenix (SNGX) Stock Soars 72% On ThermoVax Platform Promise Amid Ebola Outbreak Caused By Bundibugyo V - Benzinga
Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo - PR Newswire
$Soligenix (SNGX.US)$ thank - Moomoo
Soligenix (SNGX) Q1 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates, Stock SlipsTop Trending Breakouts - Newser
Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
Soligenix (SNGX) Down -5.08% — Is the Sell-Off Overdone? 2026-05-21Retail Trader Picks - Newser
Soligenix (SNGX) price target decreased by 60.00% to 6.12 - MSN
Soligenix (SNGX) Crushes Q4 2025 Estimates — EPS $-0.28 Tops ViewsIntrinsic Value - Newser
TradingKey - TradingKey
SNGX News | SOLIGENIX INC (NASDAQ:SNGX) - ChartMill
Soligenix (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting - USA Today
Soligenix | 424B3: Prospectus - Moomoo
Soligenix (SNGX) registers 1,054,688 resale shares; Q1 cash $6.03M - Stock Titan
Soligenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
HyBryte CTCL trial halted as Soligenix (SNGX) faces going concern risk - Stock Titan
Soligenix halts Phase 3 FLASH2 trial for CTCL due to futility, plans data analysis and strategic options. - Pluang
Soligenix Announces Recent Updates and First Quarter 2026 Financial Results - Lelezard
Soligenix (SNGX) Faces Setback in FLASH2 Study Results - GuruFocus
Soligenix Releases Q1 2026 Financial Results - AlphaStreet
Soligenix 1Q Loss/Shr 28c >SNGX - Moomoo
Soligenix Announces Recent Updates And First Quarter 2026 Financial Results - TradingView
Soligenix Anticipates HyBryte™ Phase 3 Results in Second Half of 2026, Reports $28.3 Million in Cash - geneonline.com
Soligenix Q1 net loss narrows on lower expenses - TradingView
SNGX stock slumps to record low after lymphoma trial fails – all eyes now on Behçet’s disease treatment - MSN
A. G. P. Maintains Soligenix(SNGX.US) With Buy Rating, Cuts Target Price to $1.5 - Moomoo
Soligenix (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation - USA Today
Weekly Buzz: FDA Okays Saphnelo Pen, EC Clears Acromegaly Drug, SNGX Slumps, LGND Snaps Up XOMA - RTTNews
SNGX phase 3 trial halted on HyBryte - MSN
SNGX: FLASH2 Trial Recommended to Stop for Futility - Yahoo Finance
Soligenix signals pivotal year with new drug progress - Community News
Soligenix Halts FLASH2 Trial, Explores Strategic Alternatives - TipRanks
Soligenix Inc Azioni (SNGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.00%
3.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):